Buy Traykor pills 145mg №30
  • Buy Traykor pills 145mg №30

Tricor pills 145mg №30

$47.50
Quantity

  • All payments are encrypted via SSL All payments are encrypted via SSL
  • Full Refund if you haven't received your order Full Refund if you haven't received your order

Active ingredient and dosage form

TRYCOR film-coated tablets:
1 tab. contains fenofibrate (micronized) 145 mg;
Excipients: sucrose - 145 mg; sodium lauryl sulfate - 10.2 mg; lactose monohydrate - 132 mg; crospovidone - 75.5 mg; MCC - 84.28 mg; colloidal silicon dioxide - 1.72 mg; hypromellose - 29 mg; sodium dusate - 2.9 mg; Magnesium stearate - 0.9 mg;
shell (Opadry OY-B-28920): 25.1 mg (polyvinyl alcohol - 11.43 mg; titanium dioxide - 8.03 mg; talc - 5.02 mg; soy lecithin - 0.5 mg; xanthan gum - 0, 12 mg);
Pack of 10, 20, 28, 30, 50, 84, 90, 98, 100, 280 or 300 pieces;

film coated tablets;
1 tab. contains fenofibrate 160 mg;
Excipients: sodium lauryl sulfate - 5.6 mg; lactose monohydrate - 138.4 mg; Povidone - 160 mg; Crospovidone - 96 mg; MCC - 115 mg; colloidal silicon dioxide - 12.6 mg; sodium fumarate - 6.4 mg;
shell (Opadry OY-B-28920): 28 mg (polyvinyl alcohol - 12.75 mg; titanium dioxide - 8.96 mg; talc - 5.6 mg; soy lecithin - 0.56 mg; xanthan gum - 0.13 mg );
Pack of 10, 20, 28, 30, 50, 84, 90, 98 or 100 pcs.

Mechanism of action

Tricor has a lipid-lowering effect.

Indications and usage

Hypercholesterolemia and hypertriglyceridemia isolated or mixed (dyslipidemia type IIa, IIb, III, IV, V) (Table. 145 mg) and (dyslipidemia type IIa, IIb, III *, IV, V *) (Table 160 mg) in patientsfor which diet or other non-drug therapeutic measures (for example, weight loss or increased physical activity) have been ineffective, especially if there are risk factors associated with dyslipidemia, such as hypertension and smoking;
secondary hyperlipoproteinemia in cases where hyperlipoproteinemia persists despite effective treatment of the underlying disease (for example, dyslipidemia in diabetes mellitus).
When using the drug Tricor patients should follow a diet that they followed before the start of treatment.
* Only a few patients with type III and V dyslipidemia took part in clinical studies.

Contraindications

Hypersensitivity to fenofibrate or other components of the drug;
severe liver failure (including liver cirrhosis);
severe renal insufficiency (Cl creatinine 1/100, 1/1000, 1/10000,